Physicians will monitor the patient's levels of prostate specific antigen (PSA), a marker of disease progression. (scientificamerican.com)
The patients with bone metastases did not necessarily have an elevated prostate specific antigen level. (sciencedaily.com)
Olaparib stopped prostate cancer growth, generating falls in prostate specific antigen (PSA) levels, falls in circulating tumour cell counts in the blood, and radiological responses on CT scans and MRI. (sciencedaily.com)